The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model.

Cirugia y cirujanos Pub Date : 2024-01-01 DOI:10.24875/CIRU.23000072

Caglayan Ates, Berna Dilbaz, Seval Yılmaz Ergani, Fuad Atabay

{"title":"The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model.","authors":"Caglayan Ates, Berna Dilbaz, Seval Yılmaz Ergani, Fuad Atabay","doi":"10.24875/CIRU.23000072","DOIUrl":null,"url":null,"abstract":"Objective: The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.Material and methods: Surgically induced endometriosis in Wistar albino female rats. Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le). Then, Af, aflibercept, and Le received leuprolide acetate. The control group was not treated. The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score. Blood extracted for sacrifice was analyzed. Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31). Significance level was accepted as p < 0.05.Results: Aflibercept significantly reduced endometrial implant volume (p = 0.002). The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002). Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate. Aflibercept improved adhesions (p = 0.006).Conclusion: Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.","PeriodicalId":93936,"journal":{"name":"Cirugia y cirujanos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia y cirujanos","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/CIRU.23000072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.

Material and methods: Surgically induced endometriosis in Wistar albino female rats. Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le). Then, Af, aflibercept, and Le received leuprolide acetate. The control group was not treated. The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score. Blood extracted for sacrifice was analyzed. Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31). Significance level was accepted as p < 0.05.

Results: Aflibercept significantly reduced endometrial implant volume (p = 0.002). The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002). Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate. Aflibercept improved adhesions (p = 0.006).

Conclusion: Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗血管生成剂 aflibercept 对手术诱发的大鼠子宫内膜异位症的影响。

研究目的本研究旨在首次展示阿弗利百普对子宫内膜异位症病变的影响：手术诱导Wistar白化雌性大鼠患子宫内膜异位症。将患有子宫内膜异位症的大鼠随机分为三组：对照组（Co）、阿弗利百普（aflibercept）组（Af）和醋酸亮丙瑞林（Le）组。然后，Af、aflibercept 和 Le 组接受醋酸亮丙瑞林治疗。对照组未接受治疗。根据布劳尔粘连评分记录治疗前后大鼠的体重和腹腔内粘连的变化。对牺牲时抽取的血液进行分析。对子宫内膜异位病变的大小、体积、组织学和免疫组化（血管内皮生长因子 [VEGF] 和 CD31）进行评估。P<0.05为显著性水平：结果：阿弗利百普能明显减少子宫内膜植入物的体积（p = 0.002）。阿弗利百普与醋酸亮丙瑞林组（P = 0.006）以及阿弗利百普与对照组（P = 0.002）的外植体上皮组织学评分差异显著。与醋酸亮丙瑞林相比，阿弗利百普能减少血管内皮生长因子-H和CD31的表达（p = 0.001）。Aflibercept改善了粘连（p = 0.006）：结论：阿弗利百普治疗子宫内膜异位症比醋酸亮丙瑞林更成功。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cirugia y cirujanos

自引率

0.00%

发文量